NCT03249831View on ClinicalTrials.gov

A Blood Stem Cell Transplant for Sickle Cell Disease

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

January 4, 2019

Primary Completion Date

February 18, 2026

Study Completion Date

February 18, 2026

Conditions
Sickle Cell DiseaseSickle Cell DisorderHemoglobinopathiesThalassemiaAnemia, Sickle Cell
Interventions
DRUG

Cyclophosphamide

Orally daily

DRUG

Pentostatin

Intravenous

DRUG

Rabbit anti-thymocyte globulin

Intravenous

DRUG

Tacrolimus

Initially IV. If patient tolerates, convert to oral.

DRUG

Mycophenolate mofetil

IV or oral

BIOLOGICAL

CD4+ T-cell-depleted Haploidentical Hematopoietic Transplant

Infusion

Trial Locations (1)

91010

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

California Institute for Regenerative Medicine (CIRM)

OTHER

lead

City of Hope Medical Center

OTHER